Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

Aged Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols / adverse effects Humans Immunoconjugates Lymphoma, Large B-Cell, Diffuse / drug therapy Neoplasm Recurrence, Local / drug therapy Retrospective Studies Treatment Outcome
Lymphoma and Hodgkin disease immunotherapeutic approaches relapsed refractory DLBCL

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 29 9 2020
medline: 28 4 2021
entrez: 28 9 2020
Statut: ppublish

Résumé

The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with

Identifiants

DOI: 10.1080/10428194.2020.1824069 PMID: 32981410
pubmed: 32981410
doi: 10.1080/10428194.2020.1824069
doi:

Substances chimiques

Antibodies, Monoclonal 0
Immunoconjugates 0
polatuzumab vedotin KG6VO684Z6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-124

Auteurs

Yafit Segman (Y)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
ORCID: 0000-0002-9059-3887

Elena Ribakovsky (E)

Hematology Division, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, Israel.

Abraham Avigdor (A)

Hematology Division, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Ramat Gan, Israel.

Yair Goldhecht (Y)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Vladimir Vainstein (V)

Hematology Division, Hadassah Medical Center and the Hebrew University Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Neta Goldschmidt (N)

Hematology Division, Hadassah Medical Center and the Hebrew University Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Shimrit Harlev (S)

Department of Hematology, Rambam Healthcare Campus, Haifa and the Rappaport Faculty of medicine of the Technion, Haifa, Israel.

Netanel Horwitz (N)

Department of Hematology, Rambam Healthcare Campus, Haifa and the Rappaport Faculty of medicine of the Technion, Haifa, Israel.

Odit Gutwein (O)

Department of Hematology, Assaf Harofeh Medical Center, Tzrifin, Israel.

Ronit Gurion (R)

Institute of Hematology, Rabin Medical Center, Petch Tikvah, Israel.

Gilad Itchaki (G)

Institute of Hematology, Rabin Medical Center, Petch Tikvah, Israel.

Uri Abadi (U)

Department of Hematology, Meir Medical Center, Kfar Saba, Israel.

Anatoly Nemets (A)

Department of Hematology, Barzilai Medical Center, Ashkelon, Israel.

Orit Sofer (O)

Institute of Hematology, Hillel Yaffe Medical Center, Hadera, Israel.

Miri Zektser (M)

Department of Hematology, Soroka University Medical Center, Negev Beer Sheva, Israel.

Tamar Tadmor (T)

Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel.

Nagib Dally (N)

Hematology Unit, Ziv Medical Center, Zefat, Israel.

Kalman Filanovsky (K)

Hematology Unit, Kaplan Medical Center, Rehovot, Israel.

Merav Leiba (M)

Assuta Medical Center, Hematology Institute, Ashdod, Israel.

Nadav Sarid (N)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Noam Benyamini (N)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yair Herishanu (Y)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ron Ram (R)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Chava Perry (C)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Irit Avivi (I)

Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Outcome of relapsed/refractory diffuse large...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Outcome of relapsed/refractory diffuse large...